Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The primary aim is to evaluate the anti proteinuric effect of increasing doses of the ACE
inhibitor, lisinopril: 20, 40 and 60 mg daily in type 1 diabetic patients with hypertension
and diabetic nephropathy.
The secondary aim is to evaluate the effect on blood pressure (24 hour ambulatory blood
pressure) and kidney function (glomerular filtration rate (GFR)).
The tertiary aim is to evaluate differences in response to treatment according to
ACE/insertion/deletion (ID)-genotypes and other genetic variants in the genes of the renin
angiotensin system.
Phase:
N/A
Details
Lead Sponsor:
Steno Diabetes Center Steno Diabetes Center Copenhagen